Jaguar Health Inc.

News & Events

Press Releases

In The Media

1. REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

   ACCESS Newswire JUN 9, 2025 4:15 PM EDT
   Click here to register Discussion will focus on company's May 2025 meeting with th...
   READ ARTICLE

2. Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

   ACCESS Newswire JUN 9, 2025 9:00 AM EDT
   Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to...
   READ ARTICLE

3. Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

   ACCESS Newswire JUN 6, 2025 9:00 AM EDT
   Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Ja...
   READ ARTICLE

4. Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

   ACCESS Newswire MAY 21, 2025 8:00 AM EDT
   SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX ) ("J...
   READ ARTICLE

5. First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

   ACCESS Newswire MAY 20, 2025 9:15 AM EDT
   As announced , initial proof-of-concept (POC) results from distinct ongoing investigator...
   READ ARTICLE

6. Jaguar Health Reports First Quarter 2025 Financials

   ACCESS Newswire MAY 15, 2025 2:30 PM EDT
   The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescript...
   READ ARTICLE

7. Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

   ACCESS Newswire MAY 14, 2025 9:00 AM EDT
   Click here to register Company plans to file its Earnings Report on May 15, 2025...
   READ ARTICLE

8. Jaguar Health Celebrates National Pet Cancer Awareness Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

   ACCESS Newswire MAY 8, 2025 9:30 AM EDT
   Company's Canalevia ® -CA1 (crofelemer delayed-release tablets) prescription drug ...
   READ ARTICLE

9. Jaguar Health Provides Overview of 2025 Crofelemer-Related Catalysts

   ACCESS Newswire MAY 7, 2025 9:15 AM EDT
   Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research un...
   READ ARTICLE

10. Proof-of-Concept Results Show Crofelemer Reduced Total Parenteral Nutrition in Patients with Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome with Intestinal Failure (SBS-IF) by up to 27% and 12.5% - Potential to Modify Disease Progression in Intestinal Failure Patients

    ACCESS Newswire APR 30, 2025 8:15 AM EDT
    Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the p...
    READ ARTICLE